Literature DB >> 6492995

Novel 8 alpha-ergolines with inhibitory and stimulatory effects on prolactin secretion in rats.

H Wachtel, R Dorow, G Sauer.   

Abstract

Four derivatives of the ergot dopamine (DA) agonist lisuride (LIS), namely 6-n-propyl-lisuride (6-n-propyl-LIS), transdihydrolisuride (TDHL), 6-n-propyl-transdi-hydrolisuride (6-n-propyl-TDHL) and 2-bromolisuride (2-Br-LIS) were investigated in female rats with regard to their influence on hyperprolactinaemia induced by pretreatment with reserpine (2 mg/kg i.p., 24 h) at various intervals following their subcutaneous or oral administration (0.05 mg/kg). Two hours after administration, LIS, 6-n-propyl-LIS, and 6-n-propyl-TDHL caused a statistically significant inhibition of reserpine-induced hyperprolactinaemia of about the same extent. Eight hours after administration 6-n-propyl-LIS and 6-n-propyl-TDHL were as active as after 2 h in inhibiting prolactin (PRL) secretion whereas LIS was almost ineffective in this respect. TDHL caused a statistically significant inhibition of PRL secretion at 2 and 8 h after oral administration; this effect was less pronounced after s.c. administration. In contrast to the aforementioned derivatives 2-Br-LIS further increased the reserpine-induced hyperprolactinaemia. In normal male rats pretreatment with 2-Br-LIS (0.025-6.25 mg/kg s.c., 2 h) dose-dependently stimulated PRL secretion. The present data support the assumption of the longlasting DA agonistic action of 6-n-propyl-LIS and 6-n-propyl-TDHL and of the antidopaminergic properties of 2-Br-LIS recently derived from behavioural studies.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6492995     DOI: 10.1016/0024-3205(84)90537-x

Source DB:  PubMed          Journal:  Life Sci        ISSN: 0024-3205            Impact factor:   5.037


  4 in total

1.  Pharmacokinetics and pharmacodynamics in man of the dopamine antagonist ergot derivative, bromerguride.

Authors:  W Krause; N Sauerbrey; K J Gräf
Journal:  Eur J Clin Pharmacol       Date:  1986       Impact factor: 2.953

2.  Pharmacokinetics of bromerguride, a new dopamine-antagonistic ergot derivative in rat and dog.

Authors:  M Hilderbrand; M Hümpel; W Krause; U Täuber
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1987 Jan-Mar       Impact factor: 2.441

3.  Therapeutic efficacy of a partial dopamine agonist in drug-free parkinsonian patients.

Authors:  G U Corsini; U Bonuccelli; E Rainer; M Del Zompo
Journal:  J Neural Transm       Date:  1985       Impact factor: 3.575

4.  The effects of additional treatment with terguride, a partial dopamine agonist, on hyperprolactinemia induced by antipsychotics in schizophrenia patients: a preliminary study.

Authors:  Kojiro Hashimoto; Norio Sugawara; Masamichi Ishioka; Kazuhiko Nakamura; Norio Yasui-Furukori
Journal:  Neuropsychiatr Dis Treat       Date:  2014-08-22       Impact factor: 2.570

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.